Journal:

Article Title: RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors

doi: 10.1007/s12020-008-9129-z

Figure Lengend Snippet: RUNX1 and RUNX2 bound to Gal-3 promoter. a Schematic drawing of LGALS3 promoter, PCR-amplified regions, and putative RUNX1 and RUNX2 binding sites are shown. b ChIP assay. HP 75 cells were sonicated and incubated with anti-RUNX1 antibody. c ChIP assay. HP 75 cells were sonicated and incubated with anti-RUNX2. Immune complex was precipitated by protein A-Sepharose, DNA was extracted by phenol, and PCR amplified with 5 pairs of primers derived from Gal-3 promoter and beta-actin

Article Snippet: Antigen retrieval was performed by microwaving in 0.1 mM citrate buffer at pH 6.0 for 5 min. Antibodies used for TMA slides included Gal-3 (1:500, Vector Laboratories, Burlingame, CA), RUNX1, and RUNX2 (1:20 and 1:50, Calbiochem, La Jolla, CA).

Techniques: Amplification, Binding Assay, Sonication, Incubation, Derivative Assay

Journal:

Article Title: RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors

doi: 10.1007/s12020-008-9129-z

Figure Lengend Snippet: HP75 nuclear extract bound to oligonucleotides (probes) derived from Gal-3 promoter. EMSA was performed. EBNA system from EMSA kit was served as control. a Shift was observed with HP75 nuclear extract, super-shift was observed by adding anti-RUNX1 antibody. b HP75 nuclear extract bound to oligonucleotide (probe) derived from Gal-3 promoter region 5. Anti-RUNX2 antibody disrupted this binding. c Mutations in region 1 oligonucleotide disrupted its binding to HP75 nuclear extract. Same oligonucleotide was used as in a, but key nucleotides in two different binding sites were mutated separately. Site 1 mutation abolished its binding; site 2 mutation significantly decreased its binding to HP75 nuclear extract. d Mutation in region 5 oligonucleotide disrupted its binding to HP75 nuclear extract. Same oligonucleotide was used as in c, but key nucleotides were mutated. Nuclear extracts from Jurket and HeLa cells were served as positive controls

Article Snippet: Antigen retrieval was performed by microwaving in 0.1 mM citrate buffer at pH 6.0 for 5 min. Antibodies used for TMA slides included Gal-3 (1:500, Vector Laboratories, Burlingame, CA), RUNX1, and RUNX2 (1:20 and 1:50, Calbiochem, La Jolla, CA).

Techniques: Derivative Assay, Binding Assay, Mutagenesis

Journal:

Article Title: RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors

doi: 10.1007/s12020-008-9129-z

Figure Lengend Snippet: RUNX1 and RUNX2 upregulate Gal-3 in HP75 cells and pituitary tumors, promote HP75 cell growth. a siRNA of RUNX1 and RUNX2 knocked down RUNX1 and RUNX2 expression, Gal-3 was knocked down by either of the siRNA. GAPDH served as positive control; non-transfected and non-target siRNA served as negative controls (RT-PCR) in RNA interference experiments. First left lanes are positive controls for PCR reactions. b Densitometry for a. c [3H] Thymidine incorporation experiments showed that knockdown of RUNX1, RUNX2 slowed HP75 cell growth. d Immunohistochemistry analysis with tissue microarray showing correlation of Gal-3, RUNX1, and RUNX2 expression levels in pituitary tumors. Gal-3 was expressed by PRL and ACTH tumors, but not by GH, FSH, LH, null cell, or TSH tumors. In the normal pituitary only PRL, ACTH, and folliculostellate cells expressed Gal-3.

Article Snippet: Antigen retrieval was performed by microwaving in 0.1 mM citrate buffer at pH 6.0 for 5 min. Antibodies used for TMA slides included Gal-3 (1:500, Vector Laboratories, Burlingame, CA), RUNX1, and RUNX2 (1:20 and 1:50, Calbiochem, La Jolla, CA).

Techniques: Expressing, Positive Control, Transfection, Reverse Transcription Polymerase Chain Reaction, Immunohistochemistry, Microarray

Journal: PLoS ONE

Article Title: Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling

doi: 10.1371/journal.pone.0044400

Figure Lengend Snippet: A: paraffin sections of anterior chamber angle from a normal human eye were immunostained with anti-Gal8 antibody. (i) anti-Gal8 IgG reacted intensely with cells on the trabecular beams (arrows) and with cells in the juxtacanalicular portion of TM (arrowheads). Staining was also observed in the ECM of both portions of TM (JCT and CS) and in the wall of Schlemm’s canal. (ii) No staining was observed when the sections were not exposed to the primary antibody. SC : Schlemm’s canal, JCT : juxtacanalicular TM; CS beams : corneoscleral beams. Bar: 25 µm. B: (i) RT-PCR . Total RNA (1.0 µg) from confluent cultures of normal human TM cells was subjected to RT-PCR. The expected 191 bp fragment was amplified using Gal8- specific-primers. In each case, no components were amplified when reaction mixtures lacked reverse transcriptase (RT). (ii) qRT-PCR . Total RNA was subjected to Taq-Man RT-PCR using Gal8 specific primers. Original amplification plots of Gal8 and GAPDH mRNAs genes are shown (Ct 37.37 and 33.38 for Gal8 and GAPDH, respectively). N = 3 for each experiment; all experiments were performed twice using TM cells from two different donors with reproducible results. (iii and iv) Western Blot Analysis . Protein extracts from confluent cultures of normal human TM cells were incubated with lactogel beads and eluted first with sucrose, and then with lactose. Eluted proteins were electrophoresed, the protein blot of the gel was stained with Ponceau S (iii) and was then processed for immunostaining with goat anti-Gal8 (iv). Both the total cell extract ( T ) and the lactose eluate ( L ) contained a major 36-kDa anti-Gal8 reactive component. This component was not detected in the unbound fraction ( UB ) and in the sucrose eluate ( S ).

Article Snippet: For immunostaining, longitudinal tissue sections (5 μm) were deparaffinized and sequentially treated with a basic pH antigen retrieval reagent (R&D systems, Minneapolis, MN), normal horse serum (R&D systems), goat anti-human Gal8 (2 hr, 37°C, R&D Systems; the goat antibody is specific for Gal8 and it does not recognize other galectins including Gal3 or Gal1), biotinylated anti-goat IgG (1 hr, 25°C, R&D Systems), a freshly prepared solution of avidin-biotin-complex (R&D Systems’ Cell and Tissue Staining Kit, 30 min, 25°C) and a diaminobenzidine/H 2 O 2 reagent (R&D systems).

Techniques: Staining, Reverse Transcription Polymerase Chain Reaction, Amplification, Reverse Transcription, Quantitative RT-PCR, Western Blot, Incubation, Immunostaining

Journal: PLoS ONE

Article Title: Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling

doi: 10.1371/journal.pone.0044400

Figure Lengend Snippet: Normal human TM cells were incubated on microtiter wells coated with BSA, fibronectin, or Gal8 in DPBS, in the presence and absence of a function-blocking anti-β 1 integrin antibody (JB1A), or control mouse IgG. Following incubation at 37°C for 30 min, cells were fixed and stained with crystal violet. Attached cells in fibronectin-coated wells are set as 100% (positive control); attached cells in other wells are presented as percent of positive control. Data are expressed as mean±SEM and analyzed with one-way ANOVA. * P <0.05 vs IgG; ** P <0.01 vs media or IgG; *** P <0.001 vs media. B and C: Cell spreading assay. TM cells were fixed with 4% paraformaldehyde after adhesion for 30 min. F-actin was stained with rhodamine-labeled phalloidin and cell nuclei were labeled with DAPI. Random fields of each experimental condition were photographed, and spread areas of individual cells were quantified with ImageJ. Representative micrographs of TM cells incubated in the presence and the absence of anti-β 1 integrin antibody are shown in C. Data are presented as Box–whisker plot (after Tukey) and analyzed with one-way ANOVA. *** P <0.001 vs media or IgG. This experiment was performed three times with reproducible results. Bar: 100 µm.

Article Snippet: For immunostaining, longitudinal tissue sections (5 μm) were deparaffinized and sequentially treated with a basic pH antigen retrieval reagent (R&D systems, Minneapolis, MN), normal horse serum (R&D systems), goat anti-human Gal8 (2 hr, 37°C, R&D Systems; the goat antibody is specific for Gal8 and it does not recognize other galectins including Gal3 or Gal1), biotinylated anti-goat IgG (1 hr, 25°C, R&D Systems), a freshly prepared solution of avidin-biotin-complex (R&D Systems’ Cell and Tissue Staining Kit, 30 min, 25°C) and a diaminobenzidine/H 2 O 2 reagent (R&D systems).

Techniques: Incubation, Blocking Assay, Control, Staining, Positive Control, Labeling, Whisker Assay

Journal: PLoS ONE

Article Title: Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling

doi: 10.1371/journal.pone.0044400

Figure Lengend Snippet: A: Normal human TM cells were plated on eight-chamber glass slides coated with 20 µg/ml of recombinant human Gal8 (i–iii), 20 µg/ml of fibronectin (iv–vi), or 100 µg/ml of poly-L-lysine (vii–ix) in serum-free DMEM at 37°C for 30 min (i, iv, vii), 1 hr (ii, v, viii), and 2 hr (iii, vi, ix). Following the incubation period, cells were fixed with 4% paraformaldehyde and stained with rhodamine-labeled phalloidin. Bar: 50 µm. B: Quantification of stress fiber formation. Random fields were photographed, and cells with robust stress fibers were counted. N = 225 to 362. Data are expressed as mean±SEM and analyzed with one-way ANOVA. *** P <0.001 vs poly-L-lysine at different time points. This experiment was performed three times with reproducible results.

Article Snippet: For immunostaining, longitudinal tissue sections (5 μm) were deparaffinized and sequentially treated with a basic pH antigen retrieval reagent (R&D systems, Minneapolis, MN), normal horse serum (R&D systems), goat anti-human Gal8 (2 hr, 37°C, R&D Systems; the goat antibody is specific for Gal8 and it does not recognize other galectins including Gal3 or Gal1), biotinylated anti-goat IgG (1 hr, 25°C, R&D Systems), a freshly prepared solution of avidin-biotin-complex (R&D Systems’ Cell and Tissue Staining Kit, 30 min, 25°C) and a diaminobenzidine/H 2 O 2 reagent (R&D systems).

Techniques: Recombinant, Incubation, Staining, Labeling

Journal: PLoS ONE

Article Title: Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling

doi: 10.1371/journal.pone.0044400

Figure Lengend Snippet: A and C: Serum-starved human TM cells were incubated on chamber glass slides coated with recombinant human Gal8 in the presence of the Rho inhibitor, C3 transferase or ROCK inhibitor, Y27632, at different concentrations. After 2 hr, cells were stained with rhodamine-labeled phalloidin, and cells with robust stress fibers were enumerated. Data are expressed as mean±SEM. B and D: Cells were treated C3 transferase at 2 µg/ml (B) or Y27632 at 20 µM (D), stained with rhodamine-labeled phalloidin, and random fields were photographed. Note that cells treated with Y27632 or C3 transferase are not spread and exhibit dendrite-like structures. Bar: 50 µm.

Article Snippet: For immunostaining, longitudinal tissue sections (5 μm) were deparaffinized and sequentially treated with a basic pH antigen retrieval reagent (R&D systems, Minneapolis, MN), normal horse serum (R&D systems), goat anti-human Gal8 (2 hr, 37°C, R&D Systems; the goat antibody is specific for Gal8 and it does not recognize other galectins including Gal3 or Gal1), biotinylated anti-goat IgG (1 hr, 25°C, R&D Systems), a freshly prepared solution of avidin-biotin-complex (R&D Systems’ Cell and Tissue Staining Kit, 30 min, 25°C) and a diaminobenzidine/H 2 O 2 reagent (R&D systems).

Techniques: Incubation, Recombinant, Staining, Labeling

Journal: PLoS ONE

Article Title: Galectin-8 Promotes Cytoskeletal Rearrangement in Trabecular Meshwork Cells through Activation of Rho Signaling

doi: 10.1371/journal.pone.0044400

Figure Lengend Snippet: A: Gal8 induces phosphorylation of MLC2 in a time-dependent manner. Normal human TM cells were incubated on 100-mm dishes coated with Gal8 for 0.5, 1, and 2 hr. Following incubation, cells were lysed, and protein extracts were subjected to electrophoresis in 12% SDS-PAGE gels. Blots were probed with anti-phosphorylated myosin light chain 2 (ppMLC2) (Thr18/Ser19) antibody. The blots were subsequently stripped and reprobed with anti-MLC antibody. A representative Western blot is shown in the top panel. Images were acquired by Odyssey Infrared Imaging System, and band intensity was quantified by ImageJ (bottom panel). N = 3. B: Phosphorylation of MLC2 is inhibited by Rho and ROCK inhibitors. Normal human TM cells were serum-starved overnight and treated with C3 transferase (2 µg/ml) and Y27632 (20 µM) for 4 hr. Treated cells were detached and plated on Gal8-coated dishes for 2 hr in the presence or absence of inhibitors and were then examined for the expression levels of ppMLC2 as described in the legend to panel A. Top: A representative Western blot; bottom: quantification of ppMLC2. Data are expressed as mean±SEM and analyzed with one-way ANOVA. *** P <0.001 vs control. N = 3.

Article Snippet: For immunostaining, longitudinal tissue sections (5 μm) were deparaffinized and sequentially treated with a basic pH antigen retrieval reagent (R&D systems, Minneapolis, MN), normal horse serum (R&D systems), goat anti-human Gal8 (2 hr, 37°C, R&D Systems; the goat antibody is specific for Gal8 and it does not recognize other galectins including Gal3 or Gal1), biotinylated anti-goat IgG (1 hr, 25°C, R&D Systems), a freshly prepared solution of avidin-biotin-complex (R&D Systems’ Cell and Tissue Staining Kit, 30 min, 25°C) and a diaminobenzidine/H 2 O 2 reagent (R&D systems).

Techniques: Phospho-proteomics, Incubation, Electrophoresis, SDS Page, Western Blot, Imaging, Expressing, Control